SK50932005A3 - Spôsob prípravy N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'- bifenyl]-4-yl]metyl]-L-valínu (valsartanu) - Google Patents
Spôsob prípravy N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'- bifenyl]-4-yl]metyl]-L-valínu (valsartanu) Download PDFInfo
- Publication number
- SK50932005A3 SK50932005A3 SK5093-2005A SK50932005A SK50932005A3 SK 50932005 A3 SK50932005 A3 SK 50932005A3 SK 50932005 A SK50932005 A SK 50932005A SK 50932005 A3 SK50932005 A3 SK 50932005A3
- Authority
- SK
- Slovakia
- Prior art keywords
- biphenyl
- methyl
- tetrazol
- benzyl ester
- valine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 239000004072 C09CA03 - Valsartan Substances 0.000 title claims abstract description 12
- 229960004699 valsartan Drugs 0.000 title claims abstract description 12
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 36
- YIRBOOICRQFSOK-NSHDSACASA-N benzyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 YIRBOOICRQFSOK-NSHDSACASA-N 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- ZTFVTXDWDFIQEU-UHFFFAOYSA-N 5-[2-[4-(bromomethyl)phenyl]phenyl]-1-trityltetrazole Chemical group C1=CC(CBr)=CC=C1C1=CC=CC=C1C1=NN=NN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 ZTFVTXDWDFIQEU-UHFFFAOYSA-N 0.000 claims abstract description 4
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 claims abstract description 3
- MGBJPNDAJWSIAT-WBCKFURZSA-N benzyl (2s)-3-methyl-2-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methylamino]butanoate Chemical compound N([C@@H](C(C)C)C(=O)OCC=1C=CC=CC=1)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 MGBJPNDAJWSIAT-WBCKFURZSA-N 0.000 claims abstract 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- -1 1-triphenylmethyl-tetrazol-5-yl Chemical group 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 5
- 239000012454 non-polar solvent Substances 0.000 claims description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- RMZMWFVJTIKAHW-SSRBEJHDSA-N benzyl (2s)-3-methyl-2-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methylamino]butanoate;hydrochloride Chemical compound Cl.N([C@@H](C(C)C)C(=O)OCC=1C=CC=CC=1)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 RMZMWFVJTIKAHW-SSRBEJHDSA-N 0.000 abstract description 12
- 125000006239 protecting group Chemical group 0.000 abstract description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QWUQVUDPBXFOKF-MERQFXBCSA-N benzyl (2s)-2-amino-3-methylbutanoate;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 QWUQVUDPBXFOKF-MERQFXBCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006642 detritylation reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- JKVRTUCVPZTEQZ-UHFFFAOYSA-N tributyltin azide Chemical compound CCCC[Sn](CCCC)(CCCC)N=[N+]=[N-] JKVRTUCVPZTEQZ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- GZPZPZBRCUIQNZ-MFERNQICSA-N benzyl (2s)-3-methyl-2-[pentanoyl-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoate Chemical compound CCCCC(=O)N([C@@H](C(C)C)C(=O)OCC=1C=CC=CC=1)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 GZPZPZBRCUIQNZ-MFERNQICSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- JUINSXZKUKVTMD-UHFFFAOYSA-N hydrogen azide Chemical compound N=[N+]=[N-] JUINSXZKUKVTMD-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- CEMZBWPSKYISTN-YFKPBYRVSA-N methyl (2s)-2-amino-3-methylbutanoate Chemical compound COC(=O)[C@@H](N)C(C)C CEMZBWPSKYISTN-YFKPBYRVSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000004104 valsartan derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ20031360A CZ298685B6 (cs) | 2003-05-15 | 2003-05-15 | Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu) |
| PCT/CZ2004/000029 WO2004101534A1 (fr) | 2003-05-15 | 2004-05-14 | Procede de preparation de n-(1-oxopentyl)-n-[[2'-(1h-tetrazol-5-y1)[1,1'-biphenyl]-4-y1]methyl]-l-valine (valsartan) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK50932005A3 true SK50932005A3 (sk) | 2006-01-05 |
Family
ID=33438213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK5093-2005A SK50932005A3 (sk) | 2003-05-15 | 2004-05-14 | Spôsob prípravy N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'- bifenyl]-4-yl]metyl]-L-valínu (valsartanu) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090192318A1 (fr) |
| EP (1) | EP1622882B1 (fr) |
| JP (1) | JP2007500733A (fr) |
| AT (1) | ATE495657T1 (fr) |
| CA (1) | CA2525653A1 (fr) |
| CZ (1) | CZ298685B6 (fr) |
| DE (1) | DE602004001522D1 (fr) |
| EA (1) | EA007323B1 (fr) |
| PL (2) | PL1622882T3 (fr) |
| SK (1) | SK50932005A3 (fr) |
| UA (1) | UA81039C2 (fr) |
| WO (1) | WO2004101534A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ298471B6 (cs) * | 2004-05-19 | 2007-10-10 | Zentiva, A.S. | Soli benzylesteru N-[(2´-(1H-tetrazol-5-yl)bifenyl-4-yl)methyl]-(L)-valinu a jejich použití pro výrobu valsartanu |
| EP1661891A1 (fr) * | 2004-11-30 | 2006-05-31 | KRKA, D.D., Novo Mesto | Procédé de prépartion de valsartan |
| WO2008004110A2 (fr) * | 2006-07-03 | 2008-01-10 | Aurobindo Pharma Limited | Procédé amélioré de préparation d'un antagoniste de l'angiotensine ii |
| NZ580955A (en) | 2007-05-07 | 2012-05-25 | Cipla Ltd | Process for preparing valsartan |
| JP2010526126A (ja) * | 2007-05-07 | 2010-07-29 | シプラ・リミテッド | バルサルタンの製造方法 |
| US8530506B2 (en) | 2009-11-17 | 2013-09-10 | Mitsubishi Tanabe Pharma Corporation | Process for production of biphenyl derivative |
| WO2012002189A1 (fr) * | 2010-06-30 | 2012-01-05 | 株式会社トクヤマ | Procédé de fabrication de valsartan |
| US20130137737A1 (en) * | 2010-08-03 | 2013-05-30 | Novartis Ag | Highly crystalline valsartan |
| WO2013072924A1 (fr) * | 2011-09-27 | 2013-05-23 | Alkem Laboratories Ltd. | Procédé amélioré de préparation d'antagonistes de l'angiotensine ii et d'intermédiaires de synthèse de ceux-ci |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL97219A (en) * | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Elliptical amino compounds converted by biphenyl process for their preparation and pharmaceutical preparations containing them |
-
2003
- 2003-05-15 CZ CZ20031360A patent/CZ298685B6/cs not_active IP Right Cessation
-
2004
- 2004-05-14 EA EA200401466A patent/EA007323B1/ru not_active IP Right Cessation
- 2004-05-14 PL PL04732927T patent/PL1622882T3/pl unknown
- 2004-05-14 WO PCT/CZ2004/000029 patent/WO2004101534A1/fr active Application Filing
- 2004-05-14 JP JP2006529564A patent/JP2007500733A/ja active Pending
- 2004-05-14 SK SK5093-2005A patent/SK50932005A3/sk unknown
- 2004-05-14 CA CA002525653A patent/CA2525653A1/fr not_active Abandoned
- 2004-05-14 DE DE602004001522T patent/DE602004001522D1/de not_active Expired - Lifetime
- 2004-05-14 UA UAA200512025A patent/UA81039C2/uk unknown
- 2004-05-14 PL PL04374086A patent/PL374086A1/xx unknown
- 2004-05-14 EP EP04732927A patent/EP1622882B1/fr not_active Expired - Lifetime
- 2004-05-14 US US10/556,685 patent/US20090192318A1/en not_active Abandoned
-
2006
- 2006-02-08 AT AT04732927T patent/ATE495657T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20031360A3 (cs) | 2004-12-15 |
| DE602004001522D1 (de) | 2006-08-24 |
| PL1622882T3 (pl) | 2006-12-29 |
| WO2004101534A1 (fr) | 2004-11-25 |
| CA2525653A1 (fr) | 2004-11-25 |
| PL374086A1 (en) | 2005-09-19 |
| EP1622882A1 (fr) | 2006-02-08 |
| US20090192318A1 (en) | 2009-07-30 |
| EA007323B1 (ru) | 2006-08-25 |
| JP2007500733A (ja) | 2007-01-18 |
| EP1622882B1 (fr) | 2006-07-12 |
| CZ298685B6 (cs) | 2007-12-19 |
| ATE495657T1 (de) | 2006-07-15 |
| UA81039C2 (en) | 2007-11-26 |
| EA200401466A1 (ru) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1714963A1 (fr) | Procédé pour la préparation du Valsartan et de ses intermédiaires | |
| WO2009019303A2 (fr) | Procédé de préparation ou de purification de l'olmésartan médoxomil | |
| US20090286990A1 (en) | Process for preparing irbesartan | |
| SK50932005A3 (sk) | Spôsob prípravy N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'- bifenyl]-4-yl]metyl]-L-valínu (valsartanu) | |
| JP2007112800A (ja) | アンジオテンシンｉｉ拮抗化合物の製造方法 | |
| EP1853591B1 (fr) | Procede pour l'obtention d'un compose pharmaceutiquement actif (irbesartan) et son intermediaire de synthese | |
| SK722003A3 (en) | Process for the crystallization of losartan potassium | |
| US7880015B2 (en) | Process for the preparation of angiotensin II antagonist | |
| CA2515138A1 (fr) | Synthese de 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4,4]-non-en-4-one | |
| MX2012005025A (es) | Proceso para la elaboracion de compuestos organicos. | |
| EP1948641A1 (fr) | Meilleur procédé pour la préparation d'irbésartan | |
| US8288561B2 (en) | Process for preparing valsartan | |
| KR100809159B1 (ko) | 로사탄의 개선된 제조방법 | |
| Van Chien et al. | Synthesis of Valsartan as drug for the treatment of hypertension | |
| EP1891053A1 (fr) | Procede permettant d'obtenir des derives benzimidazole et des intermediaires de ceux-ci | |
| KR101163864B1 (ko) | 발사르탄의 제조방법 및 이에 사용되는 신규 중간체 | |
| KR101009404B1 (ko) | (에스)-엔-(1-카르복시-2-메틸-프로-1-필)-엔-펜타노일-엔-[2'-(1에이취-테트라졸-5-일)비페닐-4-일-메틸]아민화합물의 고순도 제조방법 | |
| CZ298471B6 (cs) | Soli benzylesteru N-[(2´-(1H-tetrazol-5-yl)bifenyl-4-yl)methyl]-(L)-valinu a jejich použití pro výrobu valsartanu | |
| EP1749828A1 (fr) | Procédé pour la préparation d'un récepteur de l'angiotensine II | |
| JP2010526126A (ja) | バルサルタンの製造方法 | |
| KR100995755B1 (ko) | 트리틸 칸데사르탄 실렉세틸의 개선된 제조방법 | |
| WO2008152514A2 (fr) | Procédé de préparation de l'alfuzosine et de ses sels | |
| KR20120048894A (ko) | 발사르탄을 제조하기 위한 신규한 중간체 화합물 및 이를 이용한 발사르탄 제조 방법 | |
| WO2010079405A2 (fr) | Procédé amélioré de préparation d'acide 1-(pentanoylamino)cyclopentanecarboxylique | |
| KR20010019370A (ko) | Ｎ-(4-메틸벤젠술포닐)-ｎ'-(3-아자바이시클로[3,3,0]옥탄)우레아의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Suspended procedure due to non-payment of fee |